TC BioPharm completed an upsized public offering on August 29, 2024, raising $6 million in gross proceeds. The offering included 53,558 American Depositary Shares (ADSs), pre-funded warrants to purchase up to 5,946,442 ADSs, and series H warrants to purchase up to 6,000,000 ADSs, priced at $1.00 per ADS and associated warrant.The Series H Warrants are immediately exercisable with a one-year expiration period and an exercise price of £0.76 ($1.00) per ADS. The pre-funded warrants are exercisable at $0.001 per ADS until fully exercised. Each ADS represents 200 ordinary shares of the company.The proceeds will support TC BioPharm's upcoming clinical trial focusing on relapse/refractory Acute Myeloid Leukemia, market awareness initiatives, and ongoing operational expenses. The offering was conducted under an effective registration statement filed with the SEC on Form F-1.

TC BioPharm completed an upsized public offering on August 29, 2024, raising $6 million in gross proceeds. The offering included 53,558 American Depositary Shares (ADSs), pre-funded warrants to purchase up to 5,946,442 ADSs, and series H warrants to purchase up to 6,000,000 ADSs, priced at $1.00 per ADS and associated warrant.The Series H Warrants are immediately exercisable with a one-year expiration period and an exercise price of £0.76 ($1.00) per ADS. The pre-funded warrants are exercisable at $0.001 per ADS until fully exercised. Each ADS represents 200 ordinary shares of the company.The proceeds will support TC BioPharm's upcoming clinical trial focusing on relapse/refractory Acute Myeloid Leukemia, market awareness initiatives, and ongoing operational expenses. The offering was conducted under an effective registration statement filed with the SEC on Form F-1.